Biokinetics of 111In-DTPA-D-Phe1-octreotide in nude mice transplanted with a human carcinoid tumor

Radionuclide Therapy via SSTR: Future Aspects from Experimental Animal Studies

“…The fast binding to tumour tissue implied that the physical half-life of the radionuclide should be short, but if T/NT increase with time (i.e., the retention time is longer in tumour than normal tissues), radionuclides with longer half-lives might be favourable. In the GOT1 model, all T/NT studied increased with time 3–14 days after injection of 177 Lu-octreotide [81]. Similar results were found in the GOT2 model [36].…”

Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2

“…The tumor/normal-tissue activity concentration ratio was highest for blood (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26), and muscle vs. all other tissues (Table II). The lowest tumor/normal-tissue value was Table I.…”

“…Numerous studies on radiolabeled octreotide, or octreotate, have been made on nude mice xenografted with GOT1 (14)(15)(16)(17) or NCI-H69 (18)(19)(20)(21). Studies using radioiodinated meta-iodobenzylguanidine (MIBG) have been performed in vitro or on nude mice xenografted with BON tumors (22,23).…”

An Orthotopic Model of Pancreatic Somatostatin Receptor (SSTR)-Positive Tumors Allows Bimodal Imaging Studies Using 3T MRI and Animal PET-Based Molecular Imaging of SSTR Expression

“…Most of the work that was done so far utilized subcutaneous xenografts of the pancreatic amphicrine [10] rat cell line AR42J in mice [4,11,12,13,14]. AR42J cells have been extensively characterized with respect to SSTR expression and signaling, recommending these cells for imaging studies with SST analogs [15], while reports on in vivo imaging using other NET cells are rare [16]. …”